


Details:
Company's first biologic license application (BLA) candidate TTAX01 to enter Investigational New Drug (IND) Phase 3 Trials for Diabetic Foot Ulcer (DFU) indication as first biologic product to seek FDA approval for complex Wagner Grade 3 and 4 DFUs .
Lead Product(s): TTAX01
Therapeutic Area: Podiatry Product Name: TTAX01
Highest Development Status: Phase III Product Type: Cell and Gene therapy
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable June 30, 2020